Company
5 developments in the corpus
Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Latest
Everything in the corpus, newest first.
JUN 18, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval for methadone hydrochloride REMS; establishes regulatory requirements but does not report clinical trial outcomes or efficacy evidence.
JUN 18, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval action for a risk evaluation and mitigation strategy (REMS) affecting acetaminophen–codeine combination products; does not report clinical trial data.
JUN 18, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval of a Risk Evaluation and Mitigation Strategy (REMS) for an existing hydrocodone-acetaminophen combination; confirms regulatory authorization but does not report clinical trial outcomes.
JUN 18, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval of a REMS (Risk Evaluation and Mitigation Strategy) for an existing hydrocodone-acetaminophen combination, affecting distribution and prescribing requirements for opioid-containing pain medication.
JUN 18, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval for oxymorphone hydrochloride REMS; regulatory action establishing risk mitigation strategy, not clinical efficacy data.